CD274 and neoplasm: Recently, tumor specimens from NSCLC patients treated with ICIs, were evaluated for PD‐L1 expression by immunohistochemistry and for a proliferative profile by RNA‐seq showing that cell proliferation is potentially a new biomarker of response to ICIs in NSCLC [13].